Thermo Fisher Scientific and Cerilliant Corporation to Offer Certified Solution Standards for Forensic and Clinical Research Laboratories
News Jan 06, 2010
Scientists performing drugs of abuse analysis in forensic and clinical research laboratories currently face challenges because a large number of different testing methods are used within the industry with no standardization on reagents. Cerilliant's certified Snap-N-SpikeT/ Snap-N-Shoot® solutions for the ToxSpec Analyzer offer the industry standardized solutions that are performance tested for reliability and effectiveness. Cerilliant is a global leader in providing analytical reference standards and controls to the analytical community. The company pioneered the development of ready-to-use, solution-based reference standards provided in a shelf-stable, efficient and accurate format suitable for quantitative applications.
The ToxSpec Analyzer comprises integrated software, hardware and methodologies for forensic toxicology and simplifies the process of running assays while reducing analysis time and increasing confidence in compound identification. This new collaboration will facilitate the development of analytical methodologies designed to meet clinical research and forensic toxicology laboratories' increasingly strict regulatory requirements as well as the need to process assays in a much shorter space of time. The certified solution standards come with complete certificates of analysis and require no preparation or testing, resulting in accelerated turn-around times and significant savings.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE